Laura Bessen
Vermögen: - $ am 30.06.2026
Vermögen: - $ am 30.06.2026
Laura Bessen is currently an Independent Director at C4 Therapeutics, Inc. since 2022.
Formerly, Dr. Bessen was an Independent Director at Artiva Biotherapeutics, Inc. from 2022 to 2025 and served as Vice President & Head-US Medical at Bristol Myers Squibb Co. from 2001 to 2016.
Education includes undergraduate studies at the State University of New York at Binghamton and a doctorate from New York University School of Medicine.
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 24.06.2026 | 0 ( -.--% ) | - $ | 30.06.2026 |
| Unternehmen | Position | Beginn |
|---|---|---|
| C4 THERAPEUTICS, INC. | Direktor/Vorstandsmitglied | 01.08.2022 |
| Unternehmen | Position | Ende |
|---|---|---|
| ARTIVA BIOTHERAPEUTICS, INC. | Direktor/Vorstandsmitglied | 24.06.2025 |
| BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | 01.01.2016 |
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
| Private Unternehmen | 5 |
|---|---|
Bristol Myers Squibb Co.
Bristol Myers Squibb Co. Pharmaceuticals: MajorHealth Technology Manufactures and markets biopharmaceuticals products | Health Technology |
State University of New York at Binghamton
State University of New York at Binghamton Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
New York University School of Medicine
New York University School of Medicine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
C4 Therapeutics, Inc.
C4 Therapeutics, Inc. BiotechnologyHealth Technology Develops targeted protein degradation therapeutics for the treatment of cancer | Health Technology |
Artiva Biotherapeutics, Inc.
Artiva Biotherapeutics, Inc. Pharmaceuticals: OtherHealth Technology Operates as a biotechnology company which develops natural killer cell-based therapies for patients suffering from autoimmune diseases and cancers | Health Technology |
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen